Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31349397 | 0.83 | PSMB8 (0.55) | KMOLMNATSHRCA12CA9 | |
| SCHEMBL1027569 | 0.82 | NOS1 (0.49) | KMOLMNATSHRNOS1CYP1A2 | |
| SCHEMBL7410133 | 0.81 | CA12 (0.55) | KMOCA12CA9FASNGRIN2D | |
| SCHEMBL25260021 | 0.81 | KMO (0.46) | KMOLMNATSHRNOS1CYP1A2 | |
| SCHEMBL6970927 | 0.81 | KMO (0.46) | KMOLMNATSHRNOS1CYP1A2 | |
| SCHEMBL11256608 | 0.79 | KMO (1.00) | KMOLMNATSHRNOS1CYP1A2 | |
| SCHEMBL30770947 | 0.78 | KMO (0.44) | KMOLMNATSHRNOS1CYP1A2 | |
| SCHEMBL10504041 | 0.77 | KMO (0.46) | KMOLMNATSHRNOS1CYP1A2 | |
| SCHEMBL30483748 | 0.77 | KMO (0.46) | KMOLMNATSHRNOS1CYP1A2 | |
| SCHEMBL25289763 | 0.77 | KMO (0.46) | KMOLMNATSHRNOS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3121173-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121173-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| EP-2785709-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8796296-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796296-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796296-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013079505-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013079505-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| EP-0855391-B1 | NOVEL ISOQUINOLINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1316550-A1 | 6-Acylamino-5-substituted-benzoxazol-2-one compounds and method for using them | EASTMAN KODAK COMPANY (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6515176-B1 | Disclosed is a 6-acylamino-5-substituted-benzoxazol-2-one compound having the structural formula I: Also disclosed is a method for forming a cyan dye-forming coupler from the above compound. The method and intermediate with a simplified | EASTMAN KODAK COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-5959107-A | Isoquinoline derivatives | SNOW BRAND MILK PRODUCTS CO., LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0855391-A1 | NOVEL ISOQUINOLINE DERIVATIVES | SNOW BRAND MILK PRODUCTS CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| US-4438126-A | Lower alkanoic acid derivatives of 2-oxo-benzoxazolines and aldose reductase inhibiting compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4370340-A | ANTIDIABETIC AGENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | KMO 994/4885LMNA 4361/4885TSHR 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.